A contract research organization (CRO) advancing the latest in drug development with leading sponsors, worldwide. KCAS Bio is a top-tier contract research organization (CRO) that has 45 years of experience with both large pharma and biotech sponsors, providing comprehensive bioanalytical drug development services from early discovery through registration. We have supported more than 300+ FDA approved drugs on the market, developed 5,000+ proprietary and non-proprietary assays to date, and undergone 18 FDA audits with no major findings. Our presence in multiple locations throughout the US and Europe - and with a strategic alliance in Australia - allows us to serve …

140 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Discovering from Green - Scientific research aimed at obtaining plants with better productivity, fruit quality or with high -value added properties (of interest to the consumer, farmers and the agri -food industry) and more stress resistant, as well as less dependent on chemical treatments, in order to contribute to less aggressive agriculture with the environment. - Advanced genomics, proteomic, metabolomic, bioinformatics, microscopy, quantification of plant hormones, DNA sequencing and gene expression analysis. - Training of research personnel. Biotechnology, Molecular Biology, Genomic, Proteomic, Bioinformatics, Metabolomics, Systems Biology, and Synthetic Biology

245 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Seed Therapeutics is pioneering the science of improving human health by creating “molecular glues”: novel therapeutics that degrade disease-causing proteins that have heretofore remained “undruggable.” Through ongoing collaborations with world-leading academic experts in the field, and in partnership with seasoned drug development and commercialization experts, Seed Therapeutics is establishing a growing pipeline of exciting drug candidates on a path to clinical and commercial success. Our mission is to positively impact human health by creating novel protein degradation therapeutics for the treatment of severe diseases for which health care professionals currently have limited options to offer to patients. Biotechnology, Biotherapeutics, Cell …

94 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Drug discovery with cutting-edge AI technology We’re pioneering the use of AI and shaping the future in drug discovery, significantly cutting costs and development times. Our unique AI algorithms have generated novel drug candidates and identified enhancements for existing therapies more efficiently than traditional methods, setting us apart in the competitive landscape. Artificial Intelligence, Data Science, Health, Medicines, and Drug development

141 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Reducing the gap between Lab and Clinical Trials with Physiological and Pathological Non-Animal Models Unique R&D platform of donor-derived real human adipose tissue ex vivo models for pharmaceutical drug development (obesity, chronic metabolic diseases), dermo-cosmetic, nutraceutical, aesthetic and reconstructive surgery research. ExAdEx-Innov owns exclusive worldwide rights to ExAdEx patented breakthrough technology to develop preclinical models derived from human adipose tissue obtained from patients. These models maintain their native 3D structure, stem cells, functionality, and vascularization over the long term in culture, providing a faithful representation of clinical conditions. They enable the pharmaceutical industry to generate reliable human data in the …

101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

402 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Dedicated to developing treatments for rare diseases originated from nonsense mutations Genvade aims to harness the power of nonsense mutation readthrough molecules to develop treatments for some of the most burdensome rare diseases. Our lead compound targets indications include cystic fibrosis, Duchenne muscular dystrophy and other genetic diseases. small molecules, drug discovery and development, rare diseases, nonsense mutation corrector, cystic fibrosis, genetic diseases, oncology, readthrough, and Duchenne

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

205 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Neocor is dedicated to pioneering transformative therapies in cardiac care We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials. The Company was founded in October and has received strong traction since inception. We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials. gene therapy, biotechnology, rare disease, and cardiology

118 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Smartox Biotechnology is specialized in peptide research and manufacturing Smartox Biotechnology is specialized in peptide research and engineering. Peptide synthesis, physiology, pharmacology, neuroscience, ion channel research, toxin, venomous animals, and screening library

331 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Causeway Sensors uses nanotechnology to provide better candidate selection during drug development. The company spun-out after years of high-impact research at Queen's University Belfast. Our unique nanochip platform brings real-time, label-free kinetic analysis to areas of biotherapeutic production where such data cannot currently be collected. More data at critical points of production helps pharma companies ensure that only the best drug candidates progress to clinical trials. The platform can be incorporated into a multitude of form factors, ranging from a high-throughput screening instrument to an in-line cell culture monitoring tool. Biosensing, Protein - Protein Interactions, Binding Kinetics, Biotechnology, Biotherapeutics, Antibody …

90 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com. immuno-oncology

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Arrowhead Pharmaceuticals we are breaking the mold of medicine. We are pushing the boundaries of therapeutic development and revolutionizing how we care for hard-to-treat illnesses. As a company we harness collaboration and innovation to rapidly advance drugs from discovery to the clinic. All applicants: Please be aware of employment scams using Arrowhead’s name and the names of Arrowhead’s employees. All job related Arrowhead communication should come from the domain @arrowheadpharma.com. Biotech, Drug Development, Pharmaceuticals, and RNAi

66 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

We Use Small Molecules To Modify RNA Splicing Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com.

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A Member of the Roche Group Poseida was acquired by Roche in early 2025 and is now part of the Roche Group. Poseida is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral DNA Delivery System, Cas-CLOVERTM Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Genome Engineering, CAR-T cells, Gene Therapy, Gene Editing, Cell Therapy, Adoptive Cell Therapy, Multiple Myeloma, Prostate Cancer, Transposon, Non-viral, Biotechnology, Immunotherapy, Regenerative …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Abzena is the leading end-to-end bioconjugate & complex biologics CDMO+CRO, focused on rapidly moving medicines forward. Abzena is the leading end-to-end bioconjugate, ADC, and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, …

74 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Pioneering inhaled medications for cardiovascular conditions InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route. The lead product under development is an inhaled therapy to treat a common atrial arrhythmia, paroxysmal atrial fibrillation (PAF). Cardiovascular, Inhalation therapy, Biotechnology, Pharmaceuticals, Clinical Development, Drug Formulation, Commercialization, Clinical Research, Pre-Clinical Research, and Regulatory Affairs

86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing allogeneic TCR-NK therapies for solid tumors Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable. For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Peptide-based therapeutics for treating peripheral pain conditions At Akasi Pharma, we are developing novel peptide-based therapeutics to treat peripheral pain conditions Peptide therapeutics and Peripheral Neuropathic Pain

137 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Led by humans. Empowered by AI InVirtuoLabs is a new-generation laboratory for drug discovery. We design novel drugs by combining advanced machine learning techniques with physics-based simulations to rapidly identify and optimize promising drug candidates.

84 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

A scalable in-vivo genetic medicine platform At Immitra Bio, we are pioneering a novel genetic medicine platform. Our innovative approach enables precise, durable, and safe gene modifications within blood stem cells, laying the foundation for scalable, curative in-vivo therapies.

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Bioscibex, we are redefining bioprocessing with innovative single-use bioreactor solutions tailored for modern biologics and cell therapy manufacturing. Our mission is to empower researchers and manufacturers with tools that simplify processes, enhance scalability, and improve efficiency.

262 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Targeting CCN signaling to treat fibrosis Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

166 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

From molecule to medicine Unlocking the protein universe to discover the medicines of tomorrow Cyclica has been acquired by Recursion! Please follow @Recursion on LinkedIn and @RecursionPharma on Twitter to receive updates on our next chapter. Drug Development, Network Pharmacology, Drug Repositioning, Proteomics, Clinical Trials, Side Effects, Bioinformatics, Systems Biology, Drug Discovery, Artificial Intelligence, polypharmacology, medicines, Machine learning, pharmacology, pharmaceuticals, and bioinformatics

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I. A.I. - Machine Learning

A novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) PDC*line Pharma is a clinical-stage Biotechnology company that develops a new class of potent, off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a robust preclinical package and a first-in-human phase Ib in melanoma, PDC*line Pharma reported promising Phase I/II results in lung cancer (PDC*lung) in 2024. Preparations are now underway for a randomized Phase II trial in lung cancer, and a Phase Ib trial in colorectal cancer with neoantigens (PDC*neo). The company has raised €61M …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases. Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress. BioNTech was founded in …

41 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Smart active ingredients, safer sun exposure Catalonia Exponential Leader 2023 Roka Furadada’s mission is to reduce the incidence of skin cancer through research, development and production of active ingredients and medical devices, with high efficiency and low toxicologic and environmental impact OUR PURPOSE Roka Furadada wants to help to prevent and reduce the incidence of skin cancer. HOW ARE WE GOING TO DO IT? Developing the first intelligent ultra violet radiation filter: SMART UV, with new molecules that entail therapeutic activity to prevent and treat diseases associated with sun exposure. Cosmetics, Raw Materials , Ingredients, Cosmetic Ingredients, Sunscreen, Sun protection …

36 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Improving the lives of patients with immune-mediated diseases through Al-driven precision medicine Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of patients are left without adequate treatment options - and AI trained with complex disease data can solve this.

26 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus. Anti-Infectives, Drug Discovery, Antibiotics, and Microbiology

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

marine-inspired molecules to fight immunological diseases Olgram is a biotechnology company developing first-in-class, proprietary immunotherapies to treat immune deficiencies, beginning with immuno-depression after traumatic brain injury and concussion. Biotechnologie, immunologie, antibiorésistance, and commotions

69 similar entities Type: Startup Activities: deeptech biotech

Advanced molecular analysis technologies to harness the power of the microbiota. To be more responsive, more efficient and make better decisions, BforCure allows public and industrial stakeholders to access biological information in real time, thanks to an innovative technology of rapid biodetection.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

#EnablingSuccess Sygnature Discovery is a world-leading integrated drug discovery contract research organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over 1,000 employees, which includes 900 scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature Discovery has delivered 50 novel pre-clinical and 30 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more. Founded …

75 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

in vivo testing at the in vitro scale At Nagi Bioscience, we develop cutting-edge biological testing solutions enabling scientists to generate the insights they need to fuel life-changing discoveries in a faster, more efficient, and ethical way. Our pioneering Organism-on-Chip platform, SydLabTM One, seamlessly integrates into existing lab environments, enabling scientists to enhance efficiency, accuracy, and reproducibility like never before. By combining this innovative technology with our team’s expertise, we deliver customer-focused solutions that empower scientists to advance research and drive scientific thinking forward. #inwormwetrust Microfluidic technology, Drug Screening, Pre-clinical studies, Lab Automation Technology, Safety and Efficacy, Toxicology, AI, C. …

187 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

For humanity to thrive, we need transformative thinking in how vaccines and therapeutics are designed and produced. At Univercells, we believe in the power of small adaptations to drive big change. We embrace the spirit of evolution in everything we do. We are biotech innovators. We are scientists and entrepreneurs creating transformative platforms for the pharmaceutical and biotech industry, through technology, bioprocess know-how and entrepreneurial spirit. Biotechnology, mRNA, CDMO, and Services

84 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology

Powering the next wave of genetic medicines through superior delivery ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology

85 similar entities Type: Startup Activities: deeptech biotech nanotech Technologies: Synthetic Biology

Defy Limits. Deliver Results. Made Scientific is a leading cell therapy contract development and manufacturing organization (CDMO) dedicated to advancing the field of cell therapy. Since 2019, the company has specialized in developing, manufacturing, and releasing autologous and allogeneic cell therapy products for early- to mid-stage clinical trials, and has evolved into an end-to-end clinical-to-commercial service provider. Operating from two U.S.-based manufacturing facilities, Made Scientific combines the flexibility and entrepreneurial spirit of a specialist CDMO with the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors. CDMO, Process Development, Analytical …

87 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Harnessing the power of adult stem cells to develop curative therapies for cancer and autoimmune diseases Our genetically engineered, iPSC-derived cell products are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of …

100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Tackling the toughest cancers. We’re OxSonics, a pioneering clinical-stage therapeutics company committed to developing a ground-breaking platform technology to make anti-cancer drugs smarter, act faster and, above all, work better. Our SonoTran® Platform has been designed to actively enhance the delivery of oncology drugs into solid tumours. SonoTran® is drug agnostic and requires no drug reformulation enabling its use with both existing and novel therapies. We have our own development programs as well as collaborations with Pharmaceutical and biotech companies to work to bring smarter, faster and better therapies to as many patient groups as possible. Drug Delivery, Oncology, Medical …

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

TriSalus Life Sciences® seeks to transform outcomes for patients with solid tumors TriSalus Life Sciences is an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors.

137 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.

55 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming Women’s Health with Breakthrough Cancer Diagnostics and AI AOA Dx is leading a revolutionary breakthrough in early-stage cancer detection for women, leveraging the transformative potential of AI and our proprietary biomarker technology. At the heart of this innovation is our GlycoLocate platform, a multi-omics approach powered by tumor marker gangliosides, lipids and proteins. This platform is setting a new gold standard in the quest for life-saving early cancer diagnostics. We are now advancing AKRIVIS GDTM, a cutting-edge liquid biopsy test designed specifically for the early detection of ovarian cancer. Medical Devices, Diagnostics, Prognostics, Biotechnology, Sales, Commercialization, Regulatory, Licensing, Quality, …

55 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Advancing Discovery Molecular Devices is one of the world’s leading providers of high-performance life science technology. We make advanced scientific discovery possible for academia, pharma, and biotech customers with platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. From cancer to COVID-19, we've contributed to scientific breakthroughs described in over 230,000 peer-reviewed publications. Over 160,000 of our innovative solutions are incorporated into laboratories worldwide, enabling scientists to improve productivity and effectiveness – ultimately accelerating research and the development of new therapeutics. Molecular Devices is headquartered in Silicon Valley, Calif., with best-in-class teams around the globe. Over …

49 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Boosting the body's ability to defend against the damage of aging Five Alarm Bio is a drug discovery company based in Cambridge, UK focusing on novel approaches to anti-aging, with broad potential therapeutic application. We are researching therapeutics that boost the body's ability to defend against the damage of aging.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cell & Gene Therapy: Automated. Scalable. Accessible Limula provides an innovative solution for the production of the most personalised cancer treatments on demand and at scale. Our product is a unique proprietary platform can perform multiple steps of cell therapy manufacturing in a single device, using end-to-end automation and integrated process analytics. Bioproduction, Immunooncology, Cell therapy, Biotechnolgoy, Manufacturing, and CAR-T

132 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Engineering the future of RNAi-based medicines Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

85 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

World leaders in neutrophil immunotherapies to rejuvenate immune competence in solid tumours and beyond! LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing treatment for leukaemia relapse. Spearheading the development of a novel PNP inhibitor poised to revolutionize treatment for leukaemia patients facing relapse post-stem cell transplantation. Oncology

57 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Reshaping rhBMP-2 Perspectives Relieving suffering and improving quality of life with next-generation orthobiologics. Regenerative Medicine, Biomaterials, Medical devices, Drug delivery, biotechnology, BMP2, Programmed Drug Release, and Instructive Tissue Scaffolds

192 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications: - Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. - EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in …

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology. Drug Discovery, Biotech, Oncology, Fibrosis, Lysosomal Storage Disorders, NASH, and SSc

154 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Access. Better Lives. Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars. Biopharmaceuticals, Research and Development, Biosimilars, Biotechnology, Pharmaceutical, Biogenerics, Health, Cell Line Development, Business Development, and Regulatory

232 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Accelerare le scoperte, trasformare la vita! Frontage Laboratories is a US-based Contract Research Organization (CRO) that was initially established in New Jersey in April 2001 and later relocated to Pennsylvania in 2004. As an FDA-registered and inspected global pharmaceutical development and manufacturing organization, Frontage is headquartered in Exton, PA, with an impressive network of 26 facilities spread across Pennsylvania, New Jersey, Illinois, Ohio, California, Florida, Canada, Italy, and China. We are dedicated to accelerating the development of innovative therapies by providing a broad range of science-driven and quality-focused services including drug discovery, DMPK, preclinical safety & toxicology, formulation development and …

105 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

BioProcess InternationalTM is a monthly, controlled-circulation magazine devoted to the development, scale-up, and manufacture of biotherapeutics and biodiagnostics. Each issue provides the global industrial biotherapeutic community with up-to-date, peer-reviewed information detailing the business, politics, ethics, applications, products, and services required to successfully drive biopharmaceuticals, vaccines, and biodiagnostics through the development and manufacturing process. BPI is a business unit of Informa Connect https://informaconnect.com marketing, Biopharmaceutical, biotechnology, print, electronic, online, advertising programs, bioprocessing, vaccines, monoclonal antibodies, protein therapeutics, cell therapies, gene therapy, cell therapy, and biomanufacturing

180 similar entities Type: SMB Activities: biotech deeptech martech Technologies: Synthetic Biology

MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies. Our team of 300+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer. Our products and platforms have attracted multiple partnerships with leading pharmaceutical and biotechnology companies around the globe. The Company considers its employees to be its most valuable asset and we are committed to providing opportunities for individuals to learn and grow as a means to further their professional development. MacroGenics' corporate culture promotes an atmosphere of innovation, open communication and teamwork where employees …

Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Your partner in testing solutions Abich - Lifeanalytics is the Competence Center dedicated to Cosmetics and Medical Devices. Abich laboratories develops new and updated methods on biotechnology field to verify safety and efficacy of cosmetics and medical devices. The Clinical Trials Division also performs tests on healthy volunteers under the supervision of specialised personnel and in compliance with the standards for the sustainability of cosmetic claims and medical devices. Lifeanalytics, part of the CERBA Healthcare Group, was born from the union of 60 Italian companies that have over forty years of experience in analytical services of chemistry, microbiology and biology …

Type: SMB Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Innovation focused private biotech dedicated to delivering next-generation multispecific antibody therapeutics. F-star is a private biotech, based in Cambridge UK, focused on using our world-leading, innovative bispecific antibody technology that is clinically validated, patent protected and designed to create therapeutics that help more people with cancer and other serious diseases live longer with improved lives. bispecific antibodies, immuno-oncology, Immmunotherapy, oncology, cancer, tetravalent bispecifics, cancer research, biotech, immunology, CNS, and autoimmunity

72 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

158 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Belgium biotech company providing unique pipeline of medical devices in OsteoArthritis, skin aging and ophthalmology. Capitalizing on a history of innovation and expertise in exclusive natural chitosan chemistry, KiOmed Pharma, a spinout from KitoZyme, develops a unique pipeline of medical devices that address unmet medical needs in high impact pathologies and major social burdens such as invalidating OsteoArthritis, skin aging and ophthalmology. Medical Devices & Implants, Biomaterials, Rheumatology & Joint Health, Dermatology, Biosurgery, Regenerative Medicine, Ultrapure Chitosan, and Animal-free Chitosan

88 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Delivery of vision care EyeD Pharma is a clinical stage pharmaceutical company dedicated to improving the life of patients suffering from ophthalmic diseases with unmet medical needs such as glaucoma or dry eye. We develop innovative therapeutic solutions based on sustained release polymeric micro-implants and inserts.

62 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Our mission is to focus on the unmet clinical needs of patients suffering from Tenosynovial Giant Cell Tumours (TGCT) SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases

131 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating the Development of New Medicines with Targeted Proteomics Inoviv uses a novel technology platform based on targeted proteomics to support pharmaceutical companies with biomarker test development. Proteomics, Biomarker Discovery, Translational Biomarkers, Mass Spectrometry, Targeted Proteomics, Discovery Proteomics, Biomarkers, Precision Medicine, Proteomic Analysis, Proteome Profiling , Quantitative Proteomics, Liquid Chromatography Mass-Spectrometry (LC-MS), Post-Translational Modifications (PTMs), Quantitative Biomarkers, Clinical Proteomics, Immuno-Precipitation Mass Spectrometry (IP-MS), Proteins, LC-MS Proteomics, Proteomics Services, and Protein Identification

162 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our lead programme is in the area of rare genetic kidney disease.

84 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing the state-of-the-art in nature-based healthcare solutions Adamas Biotech is a clinical stage company pioneering the development of nutraceutical-based prophylactic and therapeutic solutions for a range of clinical and wellness indications. The company is specialized in the development of bioactive molecules derived from botanicals, in particular, green tea catechins. Its initial pipeline is based on 100% natural formulations of green tea purified compounds, which are under development for use in cancer prevention, anti-aging, wound care and sports medicine.

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A new hope for patients affected by Alzheimer’s disease CaSRevolution is a research company specialized in devising innovative therapies for neurodegeneration diseases We have discovered a new mechanism that explains the progression of Alzheimer’s Disease and identified a potential therapeutic approach biotech, neurodegeneration, startup, and alzheimer

112 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Helping cancer patients to get the right drugs Cancer is a disease with millions of variations where even the most effective current treatment protocols will not work for many patients. We at AIDA believe that modern high-performance computing and machine learning combined with cutting-edge gene reading tools can fast forward personalized cancer therapy and improve treatment options for cancer patients.

35 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning

Biotech company focused on cellular rejuvenation to fight cancer & degenerative pathologies. At MPC Therapeutics, we are convinced that mitochondria, the small organelles at the core of the cell's metabolism, represent untapped therapeutic targets. Headquartered in Switzerland, our startup is focused on cellular rejuvenation to improve the performance of cell therapies and treat degenerative pathologies. Our novel approach uses proprietary first-in-class small molecules that specifically target mitochondria to trigger metabolic reprogramming. Visit our website for more info. Longevity, Mitochondria, Cellular rejuvenation, Immunotherapy, and CAR T cell therapy

36 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking human potential with breakthrough mammary biotechnology. BIOMILQ is a women-owned and science-led mammary biotechnology start-up leveraging its patented technology to produce functional cell-cultured human milk components outside the body. With the goal of bridging the gap between breast milk and infant formula, BIOMILQ aims to revolutionize early-life nutrition by bringing more of the benefits of breast milk to more babies. Femtech, Biotechnology, infant nutrition, Social Venture, and Female Founder

48 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

We're on a mission to cure blindness with our transformational platform of advanced therapies Aurion Biotech is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care.

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing precision to the power of biologics with pioneering use of synthetic nanoclays for regenerative medicine. Renovos Biologics Ltd. (Renovos) is a biotech/medtech company focussed on the development of its patented synthetic nanoclay, RENOVITE®, as a drug delivery platform for regenerative medicine and beyond. Regenerative Medicine, Biomaterials, Drug Delivery, Medical Devices, Pharmaceuticals, Stem Cells, Orthopaedics, and Biotechnology

119 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing precision small molecules to combat hard-to-treat tumors. iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3Kδ and cambritaxestat is the only autotaxin inhibitor in clinical development to treat cancer. oncology, drug development, and clinical development

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

UNLOCKING THE PHOSPHATASE TARGET CLASS Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications. Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures. drug discovery, phospatase biology, and oncology

39 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A shift in cancer treatment methodology makes a world of difference. A shift in cancer treatment methodology makes a world of difference. Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA). Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme. Biotechnology, cancer, cell …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AGV Discovery offers services in chemistry, cell biology, in vitro screening, rational drug design, outsourcing and consultancy. AGV Discovery is a pharmaceutics that specializes in rational design and early development of drug candidates.

59 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Leading Diagnostic Solutions Company | Nasdaq: BDSX | 2025 & 2024 Top Workplaces Award Winner Biodesix is a leading diagnostics solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. Our culture: The foundation of Biodesix workplace culture is based on these operating principles: TEAM. IMPACT. EXCELLENCE. Based on anonymous team member …

92 similar entities Type: SMB Activities: deeptech biotech Technologies: A.I. Synthetic Biology

Providing essential, standardized tools to accelerate breakthroughs in human health Microfluidics | Cytometry | Imaging Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies. Mass Cytometry, Tissue Imaging, NGS Library Prep, Genotyping, Gene Expression, Copy Number Variation, Real-Time PCR, and Single-Cell Genomics

184 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We understand disease through the lens of the immune system for more effective, safer treatments & better diagnosis. Oncimmune has developed the most advanced and comprehensive analytical platform for the discovery of Antibody / Autoantibody Biomarker Signatures. ImmunoINSIGHTSTM, the best-in-class biomarker discovery engine, provides access to the B cell repertoire and a pivotal class of biomarkers. With one of the world’s largest antigen libraries covering 9000+ human antigens and multi-species variants, we profile antibodies from various biologic samples in very low volume (50 μl). Developed and curated by immunologists and a team of bioinformaticians, we offer high content biological insights …

74 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Addressing "undruggable"​ oncology targets by delivering whole antibodies inside the tumor and metastatic cells. Libera Bio is a preclinical stage biotech that develops new oncology treatments based on the proprietary MPN technology. This nanotechnology actively targets tumor and metastatic cells and delivers small and large molecules to on-surface, transmembrane or intracellular targets. The company is creating new treatments by delivering novel antibodies targeting intracellular oncoproteins. << Fraud Alert for Potential Candidates >> At Libera Bio, your personal information and online safety are our top priorities. • Candidates should apply exclusively through our official webpage at https://www.liberabio.com/contact/ or rrhh@liberabio.com. • If …

14 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Resolving cancer's complexity through the power of targeted drug combinations ABOUT US Mosaic Therapeutics is an oncology therapeutics company delivering precision medicines for patient groups with few targeted treatment options today. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery - leveraging our differentiated dual technology platform to advance novel combination therapies. Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active …

158 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

On-target gene therapies Alia Therapeutics is a pioneering gene editing company with a vision to revolutionize medicine by curing genetic diseases at their roots. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomic sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which are required for therapeutic applications.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Synthetic DNA production for cutting-edge biotechnology solutions. NunaBio is a privately-owned specialist DNA synthesis and development company. We are engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities. The company has built a solid reputation for its R&D flexibility and innovative approach to complex and challenging projects. NunaBio’s core expertise is research and development into cell-free DNA synthesis, process optimisation, route design, scale-up and small-scale manufacture for clinical studies. DNA, Custom DNA, Gene Synthesis, Synthetic Biology, Biotechnology, and DNA Synthesis

53 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Regenerative Biomedical Technology Allegro designs and develops a breakthrough biomedical technology for the treatment of chronic degenerative diseases in the field of musculoskeletal disease and neuroscience. Orthopaedics, Neuroscience, Rheumatology, Biopolymers, Life Sciences, Biotech, Manufacturing, and R&D

66 similar entities Type: Startup Activities: deeptech biotech

Curileum is intervening early in serious gastrointestinal (GI) disease development with novel diagnostics & therapeutics Curileum is intervening early in serious GI disease development with novel therapeutics to detect and correct cell production in the gut mucosa Biotechnology

151 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations. Clinical Grade Cell Therapy, Cancer Immonotherapy, Regenerative Medicine, and Stratified Medicine

205 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Aiming to provide improved treatments for chronic respiratory diseases through new, innovative drug substances -

382 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Reliable, reproducible, and scalable 3D in vitro platforms for drug safety & efficacy testing | The Model of ExcellenceTM InSphero is the only 3D in vitro model company with the platform and expertise to modernize drug safety and efficacy testing in a way that empowers researchers to reach their full potential. Our innovative spheroid-based models allow for more effective and safe therapies to get to the clinic faster due to our superior robustness, reliability, reproducibility, and scalability. InSphero’s goal is to help researchers fuel a new era of drug discovery through comprehensive products and services for: - Liver safety - …

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unleashing biotech innovation for a greener and fairer future For those creating a more sustainable future with biotechnology, we use AI and computational modelling to help precision fermentation alt protein companies optimise their downstream processing, so they can de-risk their ventures, speed up R&D and reduce costs. Biotechnology, Bioprocessing, Biomanufacturing, Precision Fermetation, ClimateTech, Alternative Protein, Computational Modelling, and Downstream Processing

185 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Unlocking the next generation of mRNA medicines. At Sensible, we are building the best-in-class mRNA design, optimisation and manufacturing platform to unlock the era of mRNA therapeutics and design-based biology.

64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivering therapies through targeted hyperoxygenation We are developing miniaturized hyperoxygenation therapies! The first application for our technology is miniaturized respiratory assist in patients suffering from lung failure.

58 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Light Activated Technologies for treating cancers and rare diseases Lightox has developed a new drug for the treatment of early stage oral cancers. The topically applied formulation allows for specific delivery to the lesion and is activated by a specific wavelength of light.

57 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing revolutionary biomaterials for regenerative medicine. Spiderwort Inc. is a tissue engineering company specializing in the development of transformative biomaterials for repairing and regenerating tissues within the human body.

56 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Alternative to Animal Testing for Drug Development Cherry Biotech is a biomedical technology (Organ on Chip) company that develops instruments for drug discovery and personalised medicine. Its mission is to replace animal testing by reconstructing human tissue (Organoids) in vitro for drug testing. Cherry Biotech's CUBIX platform enables pharmaceutical, biotech companies and healthcare providers to recreate immunocompetent human vascularized organ models and tumor microenvironments for better evaluation of their drug candidates. By enabling the reconstruction of human 3D models that mimic human physiology and pathophysiology over several weeks, Cherry Biotech's proprietary CUBIX technology is the only solution that can convert …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

#BeyondInnovation #DermalFiller #CYTOSIAL #AestheticMedicine New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine. Medical Device, Dermatology, Aesthetic, Cosmetic surgery, Regenerative medicine, Ultra-pure chitosan, and Hyaluronic Acid

303 similar entities Type: Startup Activities: healthtech manufacturing deeptech biotech Technologies: Synthetic Biology

Through conferences, community and market insights, we create partnerships that help advance the next pillar of medicine Phacilitate creates an environment where promising innovation can turn into the products that are changing the future of medicine. Recognised as the market leader in providing the life science sector with strategic insight, inspiration and unparalleled business networking, Phacilitate enables professionals to stay abreast of the issues driving life science innovation. #advancedtherapies #biotech #celltherapy #genetherapy Clinical Development, Cell Therapy, Gene Therapy, Oncology, Cancer, Precision Medicine, Biotech, Advanced Therapy, Biotechnology, and Life Sciences

197 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Synthetic DNA for Health & Sustainability Twist Bioscience is a synthetic biology company based in South San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, and industrial chemicals, scientists use our synthetic genes, oligo pools, biopharma services, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise …

45 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing the power of cell metabolism to develop groundbreaking disease-modifying therapies Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism. Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at …

27 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Stopping non-genetic cancer drug resistance as it emerges TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit. Drug Discovery, Drug Development, Cancer Drug …

20 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

An early-stage oncology company aiming to treat solid tumors SOLID Therapeutics is an early-stage oncology company spun out of CBMR at the University of Copenhagen. We are developing novel cancer therapeutics with dual mode of action targeting both cancer cells and immune cells to treat solid tumors.

105 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing drug delivery HHC medical is a health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Drug Delivery, Genetic therapies, and Enabling life-altering therapies

408 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology